application

Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to... » read more

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan

TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril(1) antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s... » read more

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe

TOKYO, Jan 11, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due... » read more

Audiolox Announces Early-Stage Fundraising Pledge by Investors Surpassed Its Seed Round Target by 20%

NEW YORK, NY,October 06, 2022- (SEAPRWire) – Audiolox, a blockchain-powered and secure music platform, announced that the early-stage pledges from investors were 20% higher than its seed round target. The Dubai-based company was launched on October 5, 2022, and is already attracting investors’ confidence. The event, held at the Dubai SLS hotel’s convention hall, was... » read more

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Continuously expanding the scope of potential indications for SN1011 HONG KONG, June 9, 2022 – (ACN Newswire) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is... » read more

PM Lee welcomes Canada’s application to join digital-only trade deal in phone call with PM Trudeau

Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan

TOKYO, May 10, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin (development code: E0302) for amyotrophic lateral sclerosis (ALS) in Japan, based on a favorable clinical results of the JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for... » read more

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA

HONG KONG, Apr 20, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 19... » read more

SecIron Presents Their Latest Version of IronWALL Mobile Apps Security for Huawei’s HarmonyOS Applications

Kuala Lumpur, Malaysia / SEAPRWire / July 30, 2021 / – Mobile devices like phones and tablets are no longer just communication devices for the users; they contain the very life of the users in a sense. Most users have all their information, bank statements, and other important details about themselves on their mobile devices. That is... » read more

CropLife Asia’s ‘Drone for Pesticide Application’ Online Forum draws Asian Policymakers and Global Experts

SINGAPORE, Mar 12, 2021 – (ACN Newswire via SEAPRWire.com) – A first-of-its-kind virtual conference on drone use for pesticide application in Asia concluded this week after three days of dialogue and discussion among stakeholders from across the food supply chain. The event focused on perspectives ranging from those of regional governments, manufacturers as well as... » read more

Inaugural Forum on Pesticide Application Drone use in Asia brings together Regional Policymakers and Global Experts

SINGAPORE, Mar 11, 2021 – (ACN Newswire via SEAPRWire.com) – A first-of-its-kind virtual conference on drone use for pesticide application in Asia concluded this week after three days of dialogue and discussion among stakeholders from across the food supply chain. The event focused on perspectives ranging from those of regional governments, manufacturers as well as... » read more

BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity

Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE... » read more